Biogen to Acquire Gene Therapy Company Nightstar Therapeutics
- Posted by ISPE Boston
- On March 6, 2019
Biogen has announced plans to acquire Nightstar Therapeutics (NST), a clinical-stage gene therapy company based in London, UK. NSK is focused on adeno-associated virus (AAV) treatments for inherited retinal disorders. Under the terms of the proposed acquisition, Biogen will pay $25.50 in cash for each NSK share, representing a total transaction value of about $800 […]
Read More